The deal values OpSens at about $345 million, with Haemonetics paying a 50 per cent premium on the closing price of OpSens’s shares last Friday. Shareholders and a Quebec judge have to sign off on the acquisition before it can close, which Boston-based Haemonetics’s announcement said it expects by January 2024. (The Logic)

Talking point: Haemonetics makes a range of blood-related medical equipment, from machines that separate plasma from blood at donation clinics to software for tracking patients’ blood conditions in hospitals. OpSens sells sensors to the oil and gas industry and other sectors but the companies emphasized Haemonetics’s interest in its devices for minimally invasive surgery on the heart and blood vessels. Haemonetics has manufacturing capabilities and a customer base OpSens doesn’t—and is profitable, which OpSens isn’t—but it lacks a line of fibre-optic tools.